Program
Nalbuphine
Also written as “NAL ER”, “nalbuphine HCl ER” and “Nalbuphine Hydrochloride Injection”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Prurigo · Pruritus · Chronic Cough · Opioid-Related Disorders, led by 4 companies.
Drug pageNalbuphine: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Trevi Therapeuticsits history only | 184 open or running | phase 3since May 17, 2014 | May 17, 2014 | Nov 30, 2026phase 1 · NCT07946575 |
| Lumosa Therapeuticsits history only | 10 open or running | phase 1since May 13, 2015 | May 13, 2015 | none ahead |
| Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceuticalits history only | 10 open or running | phase 3since Apr 1, 2025 | Apr 1, 2025 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 4since Jan 27, 2019 | Jan 27, 2019 | none ahead |
Also a collaborator on its studies: Parexel and Davita Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since May 17, 2014.
- May 13, 2015Lumosa Therapeutics’ first study: phase 1 study in PainNew to Lumosa TherapeuticsLumosa Therapeutics · NCT02446301 · 12 enrolled · Taiwan
- Dec 9, 2015Named nalbuphineINNProposed as its International Nonproprietary Name in WHO's List 114
- Mar 22, 2018Phase 3 study in Prurigo NodularisTrevi Therapeutics · NCT03497975 · 353 enrolled · United States, Austria, France and more
- Jan 27, 2019Yung Shin Pharm. Ind.’s first study: phase 4 study in Pain, PostoperativeNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT03826316 · 14 enrolled · Taiwan
- May 30, 20192 phase 1 studiesTrevi Therapeutics · NCT04020016, NCT04018664
- Jul 11, 2019Phase 2 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT04030026 · 42 enrolled · United Kingdom
- Jul 7, 20232 phase 2 studiesTrevi Therapeutics · NCT05964335, NCT05962151
- Apr 1, 2025Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical’s first study: phase 3 study in Postoperative AnalgesiaNew to Yangtze River Pharmaceutical Group Jiangsu Zilong PharmaceuticalYangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical · NCT06949852 · 289 enrolled · China
- May 29, 2025Phase 1 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07036029 · 9 enrolled · United States, United Kingdom
- Jun 3, 2025Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07015398 · 132 enrolled · United States
- Mar 17, 2026Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07487740 · 60 enrolled · United States
- Jun 22, 2026Phase 2 study in Chronic CoughTrevi Therapeutics · NCT07671924 · 100 planned · Canada, United Kingdom
- Jun 22, 2026Phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07671911 · 306 planned · United States
- Oct 5, 2026Phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07868419 · 201 planned · United States
- Nov 12, 2026Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07946575 · 30 planned · United States
Ahead
- Nov 30, 2026Primary completion: phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07946575
- Aug 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07868419
- Sep 2027Primary completion: phase 2 study in Chronic CoughTrevi Therapeutics · NCT07671924
- Jun 2028Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07671911
TargetBeta
“Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07946575Healthy Participants · United States | 1 | Recruiting | Trevi Therapeutics | Nov 30, 2026 | 30 |
| NCT07868419Idiopathic Pulmonary Fibrosis · United States | 3 | Recruiting | Trevi Therapeutics | Aug 2027 | 201 |
| NCT07671924Chronic Cough · Canada, United Kingdom | 2 | Recruiting | Trevi Therapeutics | Sep 2027 | 100 |
| NCT07671911Idiopathic Pulmonary Fibrosis · United States | 3 | Recruiting | Trevi Therapeutics | Jun 2028 | 306 |
| NCT07487740Healthy Participants · United States | 1 | Completed | Trevi Therapeutics | May 11, 2026 | 60 |
| NCT07015398Healthy Participants · United States | 1 | Completed | Trevi Therapeutics | Sep 12, 2025 | 132 |
| NCT07036029Idiopathic Pulmonary Fibrosis · United States, United Kingdom | 1 | Completed | Trevi Therapeutics | Jun 30, 2026 | 9 |
| NCT06949852Postoperative Analgesia · China | 3 | Completed | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical | Jul 8, 2025 | 289 |
| NCT05964335Idiopathic Pulmonary Fibrosis · Australia, Canada, Chile and more | 2 | Completed | Trevi Therapeutics | Apr 24, 2025 | 165 |
| NCT05962151Chronic Cough · Canada, United Kingdom | 2 | Completed | Trevi Therapeutics | Jan 6, 2025 | 66 |
| NCT04030026Idiopathic Pulmonary Fibrosis · United Kingdom | 2 | Completed | Trevi Therapeutics | May 27, 2022 | 42 |
| NCT04020016Hepatic Impairment · United States | 1 | Completed | Trevi Therapeutics | Feb 5, 2020 | 28 |
| NCT04018664Opioid-Related Disorders · Canada | 1 | Completed | Trevi Therapeutics | Dec 3, 2018 | 56 |
| NCT03826316Pain, Postoperative · Taiwan | 4 | Completed | Yung Shin Pharm. Ind. | Nov 22, 2018 | 14 |
| NCT03497975Prurigo Nodularis · United States, Austria, France and more | 3 | Completed | Trevi Therapeutics | May 10, 2022 | 353 |
| NCT02446301Pain · Taiwan | 1 | Completed | Lumosa Therapeutics | Apr 2015 | 12 |
| NCT02373215Uremic Pruritus | 1 | Completed | Trevi Therapeutics | Nov 2013 | 22 |
| NCT02174432Prurigo · Germany | 3 | Completed | Trevi Therapeutics | Sep 3, 2017 | 36 |
| NCT02174419Prurigo · United States, Germany, Poland | 3 | Completed | Trevi Therapeutics | Aug 2016 | 62 |
| NCT02143973Pruritus · United States | 3 | Completed | Trevi Therapeutics | Jan 2016 | 167 |
| NCT02143648Pruritus · United States, Poland, Romania | 3 | Completed | Trevi Therapeutics | Jul 2015 | 373 |
How it is read
Names in the registry
- “NAL ER”, 12 entries
- “nalbuphine HCl ER”, 2 entries
- “Nalbuphine Hydrochloride Injection”, 1 entry
- “Nalbuphine ER”, 1 entry
- “Nalbuphine ER Tablets”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 5 studies
- Prurigo, 3 studies
- Pruritus, 3 studies
- Chronic Cough, 2 studies
- Opioid-Related Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.